Posted by Michael Wonder on 17 Nov 2023
Palvella Therapeutics announces US FDA breakthrough therapy designation granted to Qtorin 3.9% rapamycin anhydrous gel (Qtorin rapamycin) for the treatment of microcystic lymphatic malformations
16 November 2023 - Qtorin rapamycin has potential to be first approved therapy and standard of care in the US for microcystic lymphatic malformations.
Palvella Therapeutics today announced that the US FDA has granted breakthrough therapy designation to Qtorin rapamycin for the treatment of microcystic lymphatic malformations.
